Angioedema Biomarker Research Study
NCT06210698
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comprehensive assessment of patients experiencing recurrent angioedema attacks, including both urticarial and non-urticarial angioedema. The primary objective is to assess the efficiency of novel diagnostic assays, both individually and in combination, in comparison to currently available commercial tests.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Angioedema
- Angioedemas, Hereditary
- Urticaria
- Mastocytosis
- ACE Inhibitor-Induced Angioedema
- C1 Inhibitor Deficiency
- Systemic Mastocytoses
- Indolent Systemic Mastocytosis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 12 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Foundation For Rare Disease Research
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Institute for Asthma and Allergy Clinical Research · Wheaton, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.